UNICYCIVE THERAPEUTICS INC. - COMMON STOCK

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

28 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

07 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

17 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

21 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

13 11 2024 07:15:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

11 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

28 10 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

16 10 2024 16:35:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

14 10 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

09 10 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

24 9 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

16 9 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 9 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

03 9 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

26 8 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

14 8 2024 07:10:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

17 7 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

11 7 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

10 7 2024 07:03:00 提供 Nasdaq GlobeNewswire

Unicycive Therapeutics Joins Russell Microcap® Index

01 7 2024 07:03:00 提供 Nasdaq GlobeNewswire